Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERSE-IT Phase 3 study of PB2452 for reversal of ticagrelor
CTR20213065Phase 3Completed
- Sponsor
- SFJ Pharmaceuticals
- Start
- Nov 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of bentracimab in Not applicable, Ticagrelor-induced impaired hemostasis (TIIH), thrombocytopathy, sponsored by SFJ Pharmaceuticals. Started Nov 2021; status: completed.
02
Drugs
bentracimab
03
Conditions
Not applicableTicagrelor-induced impaired hemostasis (TIIH)thrombocytopathy
Beyond the preview
Go deeper on CTR20213065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213065.